I te 13 o Pēpuere, 2026, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration o Haina kua whakaurua ngā papa GFH375 ki te Breakthrough Therapy Designation mō te maimoatanga o ngā tūroro e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti KRAS G12D-mutant (NSCLC) kua whiwhi i te iti rawa i te kotahi te maimoatanga pūnaha o mua.
Te Wetewete i te Waehere o te Whāinga "Undruggable"
I mua, i whakaarohia ngā whakarerekētanga KRAS e te ao hauora he whāinga "kāore e taea te rongoā". Heoi, i te whanaketanga o te rangahau pūtaiao, kei te āta wikitoriahia tēnei wero. Ko te KRAS G12D tētahi o ngā momo whakarerekētanga KRAS e kitea whānuitia ana, e kitea pinepine ana i roto i te pancreatic ductal adenocarcinoma (PDAC), te mate pukupuku pūkahukahu kore-pūtau iti (NSCLC), me te mate pukupuku colorectal.
Ngā Raraunga Hauora Whakatenatena: E Whakaatu ana a GFH375 i te Mahi Ārai-puku Kaha
Ko ngā raraunga haumanu mai i te whakamātautau Wāhanga I o GFH375 i roto i ngā tūroro he pukupuku totoka KRAS G12D-mutant kua matatau, i whakaaturia i te Hui-ā-Tau a te American Society of Clinical Oncology (ASCO) i te tau 2025, i whakarato i ngā hua whakatenatena. I whakaatu ngā raraunga i te pai o te bioavailability ā-waha me te kaha aukati pukupuku tino whiriwhiri o GFH375. I te rā kati raraunga, 62 ngā tūroro he pukupuku totoka KRAS G12D-mutant kua rongoatia i mua kua whakaurua ki te whakamātautau Wāhanga I o GFH375 monotherapy.
Ngā Rōpū Horomanga Whāinga: He Tino Whai Huatanga
I roto i ngā tūroro 49 i whiwhi i ngā horopeta ā-waha o te 400mg, 600mg rānei i ia rā, he tino mīharo ngā raraunga whai huatanga:
Te Auau Urupare Whānui (ORR): I roto i te 43 tūroro i taea te arotake, i eke te ORR ki te 42%, ā, ko te Auau Whakahaere Mate (DCR) i eke ki te 91%.
Ngā Tūroro Adenocarcinoma Ductal Repeure (PDAC): I roto i ngā tūroro PDAC e 23 i taea te arotake, ko te ORR he 52%, ā, ko te DCR i eke ki te 100%.
Ngā Tūroro Matepukupuku Pūkahukahu Ehara i te Pūtau Iti (NSCLC): I roto i ngā tūroro NSCLC 12 i taea te arotake, ko te ORR he 42%, ā, ko te DCR he 83%.
Ngā Rōpū Horomanga Katoa: He Mahi Whānui, he Mahi Hiranga hoki
I roto i te 52 o ngā tūroro i whakaoti i te iti rawa i te kotahi te aromatawai pukupuku i muri i te maimoatanga, ko te ORR puta noa i ngā rōpū horopeta katoa he 38%, me te DCR o te 90%. He mea nui, 38 ngā tūroro i pāngia e te whakahekenga o ō rātou whara whāinga, ā, 20 ngā tūroro i whiwhi i tētahi urupare hapa. E whakaatu ana ēnei raraunga tuatahi he nui te mahi aukati pukupuku a GFH375 i roto i ngā tūroro he pukupuku totoka pērā i te PDAC me te NSCLC, tae atu ki te hunga kua ahu whakamua i muri i ngā raina maha o te maimoatanga.
I te aro atu ki ēnei whanaketanga hauora hou, he mea nui te whiriwhiri i tētahi whare hauora e kaha ana ki te whakarato i ngā whiringa maimoatanga matatau me ngā ratonga whānui. E whakapau kaha ana te Tari Ao i te Hōhipera Oncology Rohe Tonga o Beijing ki te tuku ratonga tātaritanga me te maimoatanga mate pukupuku hou ki ngā tūroro o te kāinga me te ao. E mōhio tonu ana mātou ki ngā whanaketanga hou o te rangahau oncology o te ao, ā, e whakapau kaha ana mātou ki te kawe mai i ngā maimoatanga hou pēnei i te GFH375 ki ngā tūroro e hiahia ana i te wā tere rawa atu.
Ko ā mātou painga ko:
Ngā Otinga Hauora Hou: Ka mau tonu mātou i te tere o ngā paerewa o te ao, me te arotahi me te whakauru i ngā tikanga maimoatanga matatau tae atu ki te GFH375, e tuku ana i ngā whai wāhitanga rongoā pea mō ngā tūroro he whakarerekētanga KRAS G12D.
Rōpū Tohunga Maha-mātauranga: Ka huihuia e mātou ngā tohunga matepukupuku o te motu e mahi tahi ana i ngā whakawhitiwhiti kōrero maha-mātauranga hei whakawhanake i ngā mahere maimoatanga whaiaro me te whānui mō ia tūroro.
Ngā Paerewa Ratonga o te Ao: Mai i te kōrerorero, te whakarite wā, ngā ratonga whakamāori tae noa ki te tukanga maimoatanga katoa, ka whakaratohia e mātou he whakawhitiwhiti kōrero maeneene me te ratonga aro nui, kia pai ai te wheako hauora mō ngā tūroro o te ao me ō rātou whānau.
Tautoko Tūroro Whānui: E whai ana mātou kia hiranga te maimoatanga, engari e arotahi ana hoki ki te oranga hinengaro me te kounga o te oranga o ngā tūroro, me te whakarato tautoko me te manaaki whānui.
Whakapā mai ki a mātou inaianei ki te tūhura i te tumanako hou mō te maimoatanga
Mena kua tāpaetia koe, tō whānau rānei, ki te mate pukupuku pūkahukahu kore-pūtau iti KRAS G12D-mutant, ki ētahi atu pukupuku totoka rānei, ā, kāore i te pai te urupare ki ngā maimoatanga o nāianei, whakapā atu ki te Tari Ao i te Hōhipera Oncology Rohe Tonga o Beijing. Ma tā mātou tīma ngaio koe e whakarato ki ngā mōhiohio hauora hou me ngā taunakitanga tātaritanga me te maimoatanga whaiaro.
Tēnā whakapā mai ki a mātou mā ēnei huarahi e whai ake nei:
Waea: 400-880-3716
WeChat: 17801183037
Email: 100085_010@163.com 或 myimmnet@163.com
Kaua e tukua ngā arai tawhiti, ngā arai reo rānei hei arai i a koe e rapu ana i te maimoatanga matatau. Kei konei te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing hei tautoko i a koe i te pakanga ki te mate pukupuku.
Te wā tuku: 25-Pepuere-2026